Additionally, the 36-month beta value for ZOM is 0.98. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for ZOM is $0.44, The public float for ZOM is 966.01M and currently, short sellers hold a 7.28% ratio of that float. The average trading volume of ZOM on September 18, 2023 was 4.13M shares.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
ZOM) stock’s latest price update
Zomedica Corp. (AMEX: ZOM)’s stock price has decreased by -5.58 compared to its previous closing price of 0.17. However, the company has seen a -10.82% decrease in its stock price over the last five trading sessions. InvestorPlace reported 2023-09-06 that Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
ZOM’s Market Performance
Zomedica Corp. (ZOM) has experienced a -10.82% fall in stock performance for the past week, with a -17.54% drop in the past month, and a -17.62% drop in the past quarter. The volatility ratio for the week is 3.48%, and the volatility levels for the past 30 days are at 3.62% for ZOM. The simple moving average for the past 20 days is -12.53% for ZOM’s stock, with a -24.46% simple moving average for the past 200 days.
Analysts’ Opinion of ZOM
Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the current year 2023.
ZOM Trading at -19.42% from the 50-Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.00% of loss for the given period.
Volatility was left at 3.62%, however, over the last 30 days, the volatility rate increased by 3.48%, as shares sank -16.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.36% lower at present.
During the last 5 trading sessions, ZOM fell by -10.82%, which changed the moving average for the period of 200-days by -20.83% in comparison to the 20-day moving average, which settled at $0.1822. In addition, Zomedica Corp. saw -1.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZOM starting from HEATON LARRY C II, who purchase 100,000 shares at the price of $0.19 back on May 26. After this action, HEATON LARRY C II now owns 100,000 shares of Zomedica Corp., valued at $19,090 using the latest closing price.
POWERS JOHNNY D, the Director of Zomedica Corp., purchase 100,000 shares at $0.19 during a trade that took place back on May 25, which means that POWERS JOHNNY D is holding 1,600,000 shares at $19,340 based on the most recent closing price.
Stock Fundamentals for ZOM
Current profitability levels for the company are sitting at:
- -115.81 for the present operating margin
- +50.77 for the gross margin
The net margin for Zomedica Corp. stands at -89.88. The total capital return value is set at -8.10, while invested capital returns managed to touch -6.30. Equity return is now at value -7.30, with -7.00 for asset returns.
Based on Zomedica Corp. (ZOM), the company’s capital structure generated 0.65 points at debt to equity in total, while total debt to capital is 0.65. Total debt to assets is 0.62, with long-term debt to equity ratio resting at 0.41. Finally, the long-term debt to capital ratio is 0.41.
When we switch over and look at the enterprise to sales, we see a ratio of 1.97, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 14.40 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.81.
Conclusion
In conclusion, Zomedica Corp. (ZOM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
